Life sciences venture capital firms continue to evolve their approaches to translating academic research into commercial therapies. Boston-based 28 Capital, co-founded by biotech entrepreneur John Boyce and venture capitalist Audrey Warner, announced the launch of a new platform focused on developing scientific discoveries into patient treatments, building on their previous work under the Tiger Gene name.
Key Points
- The firm partners with academic founders and institutions to identify foundational science and develop it into scalable businesses across therapeutics, diagnostics, and synthetic biology.
- Co-founder John Boyce brings operational expertise with $1.8 billion in aggregate exit value and has raised over $800 million in funding throughout his career.
- Co-founder Audrey Warner contributes venture capital and corporate strategy experience.
- The founders originally met at Harvard and currently maintain active board positions across multiple portfolio companies including NanoMosaic, BrickBio, and EnCapsid Therapeutics.
This development represents another entry in the competitive biotech venture space, where firms seek to bridge the gap between academic research and commercial therapeutic development.
The Data
- Boyce has achieved $1.8 billion in aggregate exit value across his career.
- Boyce views the new platform as “doubling down on a model that combines hands-on company building with strategic capital to drive lasting impact.”
- Warner noted, “It’s about more than capital—it’s about conviction, execution, and a deep commitment to patient outcomes.”
Industry Context
At 28 Capital, we believe the future of medicine is already sitting in academic labs—our job is to unlock it, scale it, and deliver it to patients.
John Boyce, Co-Founder and Managing Partner at 28 Capital
The firm positions itself as a hands-on company builder that works directly with scientists from inception through scale. This approach involves close partnerships with academic institutions to identify promising scientific inventions and transform them into businesses. 28 Capital’s model also involves co-investing with other venture firms, strategic partners, and institutional limited partners. The company states it focuses on areas of significant unmet medical need, though specific therapeutic areas or disease targets were not detailed in the recent announcement.
